Developer of an AI-powered platform designed to generate and deploy smart contracts. The company's platform enables developers to create complex smart contracts with ease by using natural language, accelerating development time, and reducing errors.
BigHat Biosciences, Inc. is a biotechnology company based in San Carlos, California, focused on developing an automated platform for the production and characterization of antibodies. Founded in 2019, the company utilizes an AI-guided protein therapeutic platform that combines a wet laboratory with advanced machine learning techniques. This integrated approach enables the design of antibodies and other therapeutic proteins with enhanced biophysical properties and complex functions. BigHat Biosciences aims to create safer and more effective treatments for patients facing significant health challenges by leveraging its innovative capabilities in antibody engineering and biotherapeutic design.
Phaidra, Inc. specializes in designing and developing artificial intelligence solutions tailored for industrial companies in the United States. Founded in 2019 and based in Seattle, Washington, the company offers AI-powered control systems that assist large industrial facilities in learning, adapting, and enhancing their performance. Phaidra's technology analyzes extensive sensor data to create intelligent AI agents capable of automatically controlling and optimizing complex industrial processes. This innovation enables clients to improve energy efficiency and sustainability, enhance plant safety and stability, and maximize operational yield.
Swadesh is a digital banking experience built from the ground up, specifically for the Indian diaspora. They make it delightful for its customers to invest, remit and manage their money in India from abroad.
Manifold Biotechnologies, Inc. is a biotechnology company that specializes in developing platforms for the pharmacological measurement of various therapeutic protein variants. By integrating DNA technologies with machine learning, the company aims to create protein drugs that address challenging diseases. Manifold Bio's innovative approach includes a protein barcoding platform designed to enable multiplexed quantitation of protein therapeutics, thereby generating extensive data that enhances the drug development process. Founded in 2019 and located in Allston, Massachusetts, the company is focused on advancing measurement-driven design in the field of protein therapeutics.
Biopharmaceutical research and development company that's an affiliate of Clover Health
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.
Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing induced pluripotent stem cell therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company aims to create patient-specific restorative cell therapies that can alter the progression of the disease. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By integrating innovative genomic approaches with stem cell biology, Aspen Neuroscience seeks to advance the field of personalized medicine and improve treatment outcomes for patients suffering from Parkinson's disease.
Parallel Finance is a decentralized finance (DeFi) protocol that offers lending and staking services.
Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.
Nucleai Ltd. is a company that specializes in AI-powered pathology technology aimed at enhancing cancer detection and treatment. Founded in 2017 and headquartered in Tel Aviv-Yafo, Israel, Nucleai's platform analyzes tissue samples to provide insights into cancer biology, which aids in biomarker discovery and improves clinical trial outcomes. The company serves hospitals and laboratories in the United States and Israel, collaborating with leading pharmaceutical firms to license its research platform for internal applications and participate in biomarker discovery projects. By leveraging unique tissue datasets, Nucleai seeks to transform the precision oncology landscape, ultimately improving patient care.
SandboxAQ is an enterprise software company that focuses on artificial intelligence and quantum computing solutions. It provides tools designed to tackle significant challenges in various sectors, including life sciences, finance, and cybersecurity. Notably, SandboxAQ offers post-RSA cybersecurity modules that help organizations enhance their security measures through post-quantum cryptography, aligning with emerging standards in the field. The company’s software is built to facilitate cross-disciplinary collaboration, drawing from fields such as physics, computer science, neuroscience, mathematics, and cryptography. By leveraging its Large Quantitative Models (LQMs), SandboxAQ delivers innovative solutions that address real-world business and computational challenges, thereby enabling clients to advance their technological capabilities.
Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
Developer of a natural language processing software designed to build machines that understand the world and to make them safely accessible to all. The company's software provides access to language models that read multiple web pages, which also teaches users to understand the meaning, sentiment, and tone of the words, enabling businesses to improve comprehension capabilities to build more personalized user experiences.
Syllable is a developer of a text and voice-based platform designed to enhance communication between healthcare providers and patients. By leveraging artificial intelligence, the platform facilitates interactions regarding primary care, specialty referrals, vaccinations, and general practice information. This technology enables patients to access healthcare information and guidance beyond traditional clinical settings, improving overall communication and patient engagement in their healthcare journeys.
Metaphysic is a company focused on developing software for creating synthetic media that enhances human expression through ethical practices. Founded in 2021 in London by Chris Ume, Kevin Ume, and Thomas Graham, the company's technology is designed to reconstruct low-resolution footage and produce realistic facial representations. This software enables content creators to edit expressions, alter facial characteristics, and manipulate entire faces, thereby facilitating the production of immersive and engaging content for various applications, including the metaverse. By leveraging artificial intelligence, Metaphysic aims to push the boundaries of creativity and expression in digital media.
Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.
Nodexus is a biotech startup focused on providing accessible solutions for live single-cell isolation, targeting the industrial, biopharma, clinical research, and academic sectors. The company has developed the NX One platform, which features a low-cost hardware system complemented by single-use disposable microfluidic cartridges. This system is designed for various applications, including gene editing, cell line and antibody development, and studies on tumor heterogeneity. By offering affordable automated cell isolation, Nodexus aims to enhance biological workflows and extend the availability of advanced research tools to a broader range of clients.
Dialpad, Inc. is a cloud-based platform based in San Francisco, California, that specializes in enterprise communications. The company offers a comprehensive suite of services including voice, video, group messaging, SMS, MMS, conferencing, and document sharing, all powered by advanced AI technologies. Its products, such as Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, are designed to enhance collaboration and streamline communication for teams working remotely. Notably, Dialpad provides features like real-time transcription, automated note-taking, live sentiment analysis, and voice analytics, which help organizations optimize their interactions and improve decision-making. The company was founded in 2011 and has established a diverse customer base that includes notable names like Motorola Solutions and Warby Parker. Dialpad has also formed strategic alliances with major investors, including SoftBank Corp. and Salesforce Ventures, to further its mission in transforming enterprise communication.
Verge Genomics focuses on accelerating drug discovery for neurodegenerative diseases through the use of artificial intelligence and genomic data. The company has developed a platform that leverages machine learning to analyze large datasets, identifying genetic targets and predicting effective therapeutics. By mapping genes associated with various neurodegenerative conditions, Verge aims to discover drugs that can simultaneously target multiple genetic factors. Founded by experts in machine learning and neuroscience, Verge Genomics seeks to improve patient outcomes and reduce the costs associated with pharmaceutical development. The company is based in Mountain View, California, and has formed a strategic alliance with Datavant to enhance its data-driven approach.
Exai Bio is a next-generation liquid biopsy company that specializes in the early and accurate diagnosis of cancer. The company has developed a proprietary platform that analyzes cell-free RNA profiles, utilizing advanced artificial intelligence and machine learning algorithms. This technology focuses on orphan non-coding RNA and small RNA sequences that are prevalent in tumors but absent in normal tissue. By delivering clinical insights into cancer biology, Exai Bio's platform aids healthcare professionals in identifying cancer at its earliest stages and informs personalized treatment options for patients.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
MedArrive, Inc. is a New York-based startup that operates a software-as-a-service health platform designed to enhance home healthcare services. By connecting emergency medical services (EMS) professionals with patients, MedArrive enables healthcare providers to seamlessly extend care into patients' homes. The platform integrates physician-led telemedicine with hands-on support, facilitating effective communication and care management. This innovative approach allows for improved continuity of care, better patient outcomes, and cost savings for both patients and providers. Founded in 2020, MedArrive aims to bridge the virtual care gap, making high-quality healthcare more accessible to a broader population.
Arbor Biotechnologies operator of a bio-discovery company intended to provide human diagnostic development service. The company's platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, enabling drug developers to accelerate the discovery of proteins for improving human health and sustainability.
Mekonos Inc. is a technology company based in San Francisco, California, focused on the design, development, and production of gene and cell therapies. Founded in 2017, Mekonos has developed a proprietary cell-engineering platform that utilizes scalable silicon technology and an integrated system-on-a-chip. This platform enables the creation of predictive models for drug discovery and development, as well as a silicon chip automated architecture for genome editing. The company's innovative MEMS technology allows for the precise control of individual nanoneedles to inject single cells in parallel, facilitating the industrialization of engineered therapies for genetic diseases, including cancers. By providing a reliable and reusable manufacturing system, Mekonos aims to enable healthcare providers to deliver a diverse range of therapeutic molecules across various primary cell types.
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.
Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.
Developer of a biomedical language platform designed to transform unstructured biomedical data into contextualized information. The company's platform detects and extracts biomedical terms, clinical variables, and medical codes in the text links complex information to make actionable data, and connects medical concepts to perform powerful queries, providing clients easy access to medical alternatives by decoding the medical data.
Gretel Labs, Inc. develops an online platform that helps developers to create and share data. It offers data catalog, automate data exposure detection, and fast data cataloging of streaming data for fun and privacy; synthetics; and transformation, real time transformation, and data firewalling. Gretel Labs, Inc. was formerly known as Gretel, Inc. The company was founded in 2019 and is based in Poway, California.
Wise Systems Inc. develops autonomous dispatch and routing software designed to enhance the efficiency of last-mile delivery operations across various industries, including food and beverage, courier, and field service. Founded in 2014 and based in Boston, Massachusetts, the company leverages machine learning to optimize fleet performance and improve customer service. Its platform includes tools such as Scheduler for creating dynamic route plans, Dispatcher for real-time monitoring of delivery progress and performance metrics, and a Customer Portal for tracking orders with accurate ETAs. The software processes millions of data points to make intelligent, real-time decisions, resulting in significant mileage reductions, increased fleet utilization, and a substantial decrease in late deliveries. Wise Systems aims to help customers better manage their delivery logistics by providing flexibility and optimizing routes, thereby enhancing overall operational efficiency.
TRIALSPARK, INC. develops health tech platform. Its platform provides clinical trial sites with monetary compensation, medication, study visits, and study-related tests and procedures. The company was incorporated in 2013 and is based in New York, New York.
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.
Developer of a natural language processing software designed to build machines that understand the world and to make them safely accessible to all. The company's software provides access to language models that read multiple web pages, which also teaches users to understand the meaning, sentiment, and tone of the words, enabling businesses to improve comprehension capabilities to build more personalized user experiences.
Syllable is a developer of a text and voice-based platform designed to enhance communication between healthcare providers and patients. By leveraging artificial intelligence, the platform facilitates interactions regarding primary care, specialty referrals, vaccinations, and general practice information. This technology enables patients to access healthcare information and guidance beyond traditional clinical settings, improving overall communication and patient engagement in their healthcare journeys.
ImmuneID is a precision immunology company that has developed a proprietary platform aimed at identifying and therapeutically targeting antibody interactions involved in immune diseases. The platform utilizes advanced methodologies, including massively parallel, multiplexed, and unbiased systems, to facilitate the development of therapeutics for various conditions such as autoimmunity, severe allergies, oncology, and infectious diseases. By enabling researchers to observe and analyze human immune responses across different stages of disease progression, ImmuneID seeks to enhance the understanding of immune mechanisms and improve treatment strategies.
Primer Technologies, Inc. specializes in developing advanced software that employs machine learning and natural language processing to analyze extensive datasets. The company's platform is designed to read and interpret documents in multiple languages, uncover insights, and generate automated reports that rival human analysis. By facilitating the understanding of vast amounts of text data, Primer assists governments and corporations in monitoring and making sense of global information. Founded in 2015 and headquartered in San Francisco, California, Primer aims to bridge the intelligence gap for businesses and enhance their ability to respond to emerging trends in the world.
Clinical protocols are scientific decisions wrapped in administrative burden. The Faro system handles the tedious work better left for a computer, freeing clinical researchers to focus on the important decisions that drive clinical value.
Phaidra, Inc. specializes in designing and developing artificial intelligence solutions tailored for industrial companies in the United States. Founded in 2019 and based in Seattle, Washington, the company offers AI-powered control systems that assist large industrial facilities in learning, adapting, and enhancing their performance. Phaidra's technology analyzes extensive sensor data to create intelligent AI agents capable of automatically controlling and optimizing complex industrial processes. This innovation enables clients to improve energy efficiency and sustainability, enhance plant safety and stability, and maximize operational yield.
Twinstrand Therapeutics is a biopharmaceutical company that engages in the discovery, development, and commercialization of biological drugs for the treatment of life-threatening diseases. The product of the company is TST10088. It is a recombinant protein-based prodrug for activation by matrix metalloproteinases associated with solid tumor forms of cancer. Twinstrand is a Canada-based company that was founded in 1995. The company was acquired by Cangene on July 7, 2009.
Current Health Limited, founded in 2014 and based in Edinburgh, United Kingdom, specializes in developing wearable healthcare devices that monitor patients' vital signs. These devices are designed to measure key health metrics such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, allowing for the early identification of unwell patients and timely medical intervention. The company also offers a patient monitoring platform that facilitates home-based care by enabling patients to share daily activities, report symptoms, and respond to structured questionnaires for their healthcare providers. By focusing on remote patient management, Current Health aims to reduce healthcare risks and costs while enhancing patient engagement and monitoring. Formerly known as Snap40 Limited, the company rebranded in December 2018 to better reflect its mission.
C2i Genomics, Inc. specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-surgery cancer patients. The company offers an ultra-sensitive liquid biopsy assay that analyzes subtle changes in tumor DNA, enabling physicians to monitor treatment responses and detect disease recurrence or treatment failure significantly earlier than traditional methods. C2i Genomics employs a bio-platform approach applicable across various cancer types, facilitating the guidance of multiple treatment modalities, including surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, the company provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. Established in 2019, C2i Genomics is headquartered in New York, New York, with a research and development center located in Haifa, Israel.
Meatable B.V. is a food production company based in the Netherlands that specializes in the development of lab-grown meat and meat products derived from cows, chickens, and pigs. Founded in 2018, the company focuses on producing single-cell based hamburgers and aims to address concerns related to climate change, animal welfare, and food security. By utilizing innovative techniques, Meatable seeks to provide a sustainable alternative to traditional meat production, allowing consumers to enjoy real meat without compromising ethical or environmental standards. Through its efforts, the company aspires to satisfy the global demand for meat while promoting a more responsible and guilt-free approach to food consumption.
Miroculus, Inc. is a San Francisco-based company that specializes in non-invasive molecular data gathering and analysis tools. Founded in 2014, Miroculus has developed a digital microfluidics platform that automates and miniaturizes genomic protocols, making advanced molecular testing accessible to a wide range of laboratories. Their innovative cartridge-based system allows for the efficient execution of various applications, including next-generation sequencing library preparation, synthetic biology, and cell editing. Miroculus focuses on providing affordable, accurate, and minimally invasive testing solutions that enable medical practitioners to detect and monitor diseases at the molecular level. Their offerings cater to academic institutions, genomic research centers, and companies in the pharmaceuticals, biotechnology, and diagnostics sectors.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Octave Bioscience is an early-stage molecular diagnostics company based in Menlo Park, California, that specializes in neurodegenerative diseases, particularly multiple sclerosis. Co-founded in 2013 by Melinda Thomas and William Hagstrom, the company has developed a clinical platform that generates, analyzes, and integrates data to transform the care of neurodegenerative conditions. This platform adopts a multi-dimensional approach aimed at reducing overall healthcare costs through the optimization of medication use and healthcare services. Additionally, Octave's technology supports the pharmaceutical industry by enhancing the drug discovery process, clinical trials, and post-marketing activities through real-world evidence.
WithMe Health, LLC, founded in 2018 and based in San Mateo, California, specializes in medication guidance solutions aimed at enhancing the medication management experience for employers and their members. The company offers a personalized approach that tailors medication selection to individual needs, guiding members through their entire medication journey. By replacing traditional pharmacy benefit managers with its innovative platform, WithMe Health provides a comprehensive range of services that leverage advanced technology and rich datasets. This approach allows for the consistent application of proven scientific methods to deliver individualized medication experiences that are proactive, adaptive, and engaging. WithMe Health's outcomes-oriented business model not only optimizes health outcomes but also significantly reduces costs for employers, aligning interests across the pharmaceutical value chain.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.
The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine.
Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
Neocis, Inc. is a company that specializes in the development and manufacturing of robotic guidance systems for dental implant procedures. Founded in 2009 and based in Miami, Florida, Neocis has created Yomi, a robotic device designed to enhance the precision of dental implant placements. Yomi integrates computer imagery from CT scans with surgical planning, providing multi-sensory feedback to dental surgeons during procedures. The device is commercially available in the United States and has received clearance from the U.S. Food and Drug Administration. Neocis focuses on collaborating with dental professionals to address surgical challenges and improve patient care through advanced technology, promoting a minimally invasive approach that facilitates faster surgery and recovery.
Dialpad, Inc. is a cloud-based platform based in San Francisco, California, that specializes in enterprise communications. The company offers a comprehensive suite of services including voice, video, group messaging, SMS, MMS, conferencing, and document sharing, all powered by advanced AI technologies. Its products, such as Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, are designed to enhance collaboration and streamline communication for teams working remotely. Notably, Dialpad provides features like real-time transcription, automated note-taking, live sentiment analysis, and voice analytics, which help organizations optimize their interactions and improve decision-making. The company was founded in 2011 and has established a diverse customer base that includes notable names like Motorola Solutions and Warby Parker. Dialpad has also formed strategic alliances with major investors, including SoftBank Corp. and Salesforce Ventures, to further its mission in transforming enterprise communication.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.
Evidation Health develops a health data analytics platform that collects and analyzes continuous behavior data alongside healthcare information to enhance health outcomes. Founded in 2012 and headquartered in San Mateo, California, the company utilizes raw, high-frequency data from various sources such as sensors, devices, and video to generate insights into health and disease. Its products include a Data Platform, which transforms everyday behavior data into actionable health measures, and Studies, a service for conducting real-world research that incorporates behavioral data to support clinical and commercial teams. Evidation Health connects digital health companies with healthcare providers and payers, facilitating a better understanding of how everyday behaviors influence health. The company's offerings also encompass health outcomes research, technology assessment, and predictive analytics services.
Autobahn Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, dedicated to developing small molecule therapies for central nervous system (CNS) disorders. The company focuses on leveraging its expertise in brain-targeting chemistry to create innovative treatments that harness the regenerative capabilities of the human body. Its primary product candidate, ABX-002, is a thyroid hormone receptor beta agonist aimed at treating multiple sclerosis and adrenomyeloneuropathy, a rare genetic disorder. Founded in 2017, Autobahn Therapeutics is committed to addressing significant unmet medical needs in areas such as neuropsychiatry, neurodegeneration, and neuroinflammation, utilizing validated clinical and biological targets to guide its research and development efforts.
Phaidra, Inc. specializes in designing and developing artificial intelligence solutions tailored for industrial companies in the United States. Founded in 2019 and based in Seattle, Washington, the company offers AI-powered control systems that assist large industrial facilities in learning, adapting, and enhancing their performance. Phaidra's technology analyzes extensive sensor data to create intelligent AI agents capable of automatically controlling and optimizing complex industrial processes. This innovation enables clients to improve energy efficiency and sustainability, enhance plant safety and stability, and maximize operational yield.
Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing induced pluripotent stem cell therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company aims to create patient-specific restorative cell therapies that can alter the progression of the disease. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By integrating innovative genomic approaches with stem cell biology, Aspen Neuroscience seeks to advance the field of personalized medicine and improve treatment outcomes for patients suffering from Parkinson's disease.
Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.
The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine.
Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing induced pluripotent stem cell therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company aims to create patient-specific restorative cell therapies that can alter the progression of the disease. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By integrating innovative genomic approaches with stem cell biology, Aspen Neuroscience seeks to advance the field of personalized medicine and improve treatment outcomes for patients suffering from Parkinson's disease.
XOKind Inc. is an artificial intelligence software company that focuses on the travel and leisure markets. Founded in 2019 and based in San Diego, California, XOKind develops AI agents that learn users' travel preferences by analyzing their calendars, emails, photos, and social media interactions. The company aims to simplify planning and decision-making for individuals by leveraging advanced AI technology to distill information relevant to travel and leisure activities.
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
At Cradle Genomics, their mission is to provide knowledge that helps every pregnancy. They're dedicated to the transformation of non-invasive prenatal testing (NIPT) by offering the most comprehensive fetal genetic analysis and pregnancy health screening solutions at the earliest stages of pregnancy.
Cradle Genomics is newly formed with their headquarters based in San Diego and additional R&D operations located in Detroit. Cradle tests are based on the genetic analysis of fetal cells that are quickly collected during a first trimester visit with no risk to the mother or developing fetus.
Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.
Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.
MedCrypt is a cybersecurity company focused on protecting medical devices by providing data security as a service to medical device original equipment manufacturers (OEMs). Founded in 2016 and based in Encinitas, California, MedCrypt's platform incorporates essential security features that ensure medical devices, such as pacemakers and surgical robots, operate only on instructions from trusted sources. The company's solutions include user authentication, data encryption, and transaction monitoring, which help hospitals and health systems prevent unauthorized access and misuse of medical devices. By enabling engineers to integrate these security measures swiftly and efficiently, MedCrypt allows them to concentrate on developing innovative clinical features that can enhance patient care.
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.
Teckro, Inc. offers a solution that transforms clinical trials making all relevant information instantly accessible to every active member of the study. The company facilitates connections between investigators and the expertise they need; and helps study teams, sites, and patients to connect. Its solution instantly captures and shares team’s knowledge to dramatically reduce the burden on CRAs, medical monitors, data management, and study personnel. The company serves pharmaceutical companies and clinical researchers across the world. Teckro, Inc. was incorporated in 2015 and is based in Limerick, Ireland.
Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.
Ciitizen Corporation operates a digital healthcare platform that empowers patients to collect, organize, and share their personal health information, including genomic data, lab results, and advanced directives. Founded in 2017 and based in Palo Alto, California, Ciitizen aims to provide individuals with comprehensive control over their health data, facilitating seamless sharing with caregivers, researchers, and other relevant parties. The platform addresses the limitations of existing health information systems, which often provide only minimal data and require extensive manual efforts to extract insights. By normalizing unstructured health information into actionable visualizations, Ciitizen enhances the ability of patients, caregivers, and clinicians to access and utilize vital health insights efficiently. The company is led by CEO Anil Sethi and is supported by notable investors, including Andreessen Horowitz and Verily, positioning it as a key player in the evolving landscape of patient-centered healthcare data management.
Primer Technologies, Inc. specializes in developing advanced software that employs machine learning and natural language processing to analyze extensive datasets. The company's platform is designed to read and interpret documents in multiple languages, uncover insights, and generate automated reports that rival human analysis. By facilitating the understanding of vast amounts of text data, Primer assists governments and corporations in monitoring and making sense of global information. Founded in 2015 and headquartered in San Francisco, California, Primer aims to bridge the intelligence gap for businesses and enhance their ability to respond to emerging trends in the world.
Developer of a current ion source and linear accelerator intended to remove the current limitations of radioisotope manufacturing for medical application and innovation. The company offers a broad range of diagnostic and therapeutic radioisotopes which are produced uranium-free, helping healthcare sector clients develop radiopharmaceuticals for personalized cancer therapies at comparatively lower costs.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for genetically defined diseases with high unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle-wasting disorder. Another key candidate, FTX-6058, aims to increase fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia. In addition to these programs, Fulcrum is exploring drug targets for other conditions such as Duchenne muscular dystrophy, Friedreich ataxia, myotonic dystrophy 1, and various neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma and MyoKardia to advance research and develop targeted therapies for pulmonary diseases and genetic cardiomyopathies, respectively. Founded in 2015, Fulcrum Therapeutics is committed to improving the lives of patients facing significant health challenges.
Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer's and frontotemporal dementia. The company's lead product, AL001, is a humanized recombinant monoclonal antibody currently in phase II clinical trials for frontotemporal dementia. Additionally, AL101 is in phase I clinical trials for various neurodegenerative diseases, while AL002 and AL003 are undergoing phase 1b trials specifically for Alzheimer's disease. Alector is leveraging advancements in antibody technology, neuroimmunology, and human genetics to create innovative therapeutics. The company maintains a collaboration with Adimab, LLC, which aids in the discovery and optimization of antibody therapeutics. Alector has a pipeline of ten programs in the research and development stage and aims to advance several candidates through pre-clinical development within the next two years. Founded in 2013, Alector is headquartered in South San Francisco, California.
Metromile is the provider of pay-per-mile car insurance company in the U.S. Powered by data science and machine learning, the company is disrupting a $250 billion auto insurance category. Metromile is building a loyal community of drivers who come for the savings and stay for the experience.
AVA, Metromile's AI-driven claims system, is designed to speed up the process of verifying and paying out insurance claims. Using Metromile Pulse sensor data, AVA can reconstruct the scene of an accident to instantly determine if claim details are accurate. When the claim is verified, Metromile is able to automatically approve payments within seconds.
Dialpad, Inc. is a cloud-based platform based in San Francisco, California, that specializes in enterprise communications. The company offers a comprehensive suite of services including voice, video, group messaging, SMS, MMS, conferencing, and document sharing, all powered by advanced AI technologies. Its products, such as Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, are designed to enhance collaboration and streamline communication for teams working remotely. Notably, Dialpad provides features like real-time transcription, automated note-taking, live sentiment analysis, and voice analytics, which help organizations optimize their interactions and improve decision-making. The company was founded in 2011 and has established a diverse customer base that includes notable names like Motorola Solutions and Warby Parker. Dialpad has also formed strategic alliances with major investors, including SoftBank Corp. and Salesforce Ventures, to further its mission in transforming enterprise communication.
Octave Bioscience is an early-stage molecular diagnostics company based in Menlo Park, California, that specializes in neurodegenerative diseases, particularly multiple sclerosis. Co-founded in 2013 by Melinda Thomas and William Hagstrom, the company has developed a clinical platform that generates, analyzes, and integrates data to transform the care of neurodegenerative conditions. This platform adopts a multi-dimensional approach aimed at reducing overall healthcare costs through the optimization of medication use and healthcare services. Additionally, Octave's technology supports the pharmaceutical industry by enhancing the drug discovery process, clinical trials, and post-marketing activities through real-world evidence.
Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.
The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine.
Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
Celularity is a clinical-stage biotechnology company focused on developing innovative therapies using allogeneic cells and tissues derived from postpartum placenta. The company specializes in off-the-shelf placental-derived cell therapies, including both genetically modified and unmodified natural killer (NK) cells, engineered T cells such as CAR-T cells, and mesenchymal-like adherent stromal cells. These therapies are designed to treat a range of conditions, including cancer, autoimmune diseases, and degenerative disorders, while also enhancing immunity and promoting healing. Celularity operates through three main business segments: Cell Therapy, Degenerative Disease, and bio-banking, with the bio-banking segment contributing the majority of its revenue. The company aims to enable patients to initiate treatment more rapidly, thereby improving medical outcomes.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
Dave Inc. is a financial services company based in Los Angeles, California, founded in 2015. The company has developed a mobile application designed to assist users in managing their finances by providing insights into bank overdrafts and predicting expenses. The app enables users to avoid overdraft fees and low balances by offering features such as paycheck advances, budgeting tools, and resources for finding side gigs. With a focus on helping users maintain financial stability, Dave serves approximately 7 million Americans by providing essential tools for budgeting and credit building. The application is accessible on both the App Store and Google Play, positioning Dave as a key player in the challenger bank space.
Lime is a company focused on providing sustainable transportation solutions to address the first and last mile mobility challenges in urban areas. It offers an array of smart mobility options, including electric scooters and bikes, designed to be affordable and convenient for users while minimizing their carbon footprint. Lime collaborates with cities to deploy its fleet, which features electric kick-scooters and bikes equipped with GPS and self-activating locks, ensuring reliable access for riders. Through its services, Lime aims to encourage a shift in transportation behavior, promoting a greener future for urban mobility.
Kobalt is an independent music services company that provides technology-driven solutions designed to enhance transparency and efficiency for rights owners in the music industry. The company operates through its Music Publishing, Label Services, and Neighbouring Rights divisions, offering a modern alternative to traditional business models. Kobalt empowers artists, songwriters, and publishers by providing real-time reporting through its Kobalt Portal, along with global licensing management, royalty collection, and digital marketing services. With a workforce of over 275 employees and a client roster that includes prominent artists and songwriters, Kobalt represents more than 8,000 creators and 600,000 songs, significantly impacting the music charts. The company aims to ensure fair and accurate payment for its clients while navigating the complexities of the digital music landscape.
Dialpad, Inc. is a cloud-based platform based in San Francisco, California, that specializes in enterprise communications. The company offers a comprehensive suite of services including voice, video, group messaging, SMS, MMS, conferencing, and document sharing, all powered by advanced AI technologies. Its products, such as Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, are designed to enhance collaboration and streamline communication for teams working remotely. Notably, Dialpad provides features like real-time transcription, automated note-taking, live sentiment analysis, and voice analytics, which help organizations optimize their interactions and improve decision-making. The company was founded in 2011 and has established a diverse customer base that includes notable names like Motorola Solutions and Warby Parker. Dialpad has also formed strategic alliances with major investors, including SoftBank Corp. and Salesforce Ventures, to further its mission in transforming enterprise communication.
Teckro, Inc. offers a solution that transforms clinical trials making all relevant information instantly accessible to every active member of the study. The company facilitates connections between investigators and the expertise they need; and helps study teams, sites, and patients to connect. Its solution instantly captures and shares team’s knowledge to dramatically reduce the burden on CRAs, medical monitors, data management, and study personnel. The company serves pharmaceutical companies and clinical researchers across the world. Teckro, Inc. was incorporated in 2015 and is based in Limerick, Ireland.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Coinbase, Inc. is an online platform that enables merchants, consumers, and traders to buy, sell, and store digital currencies, including Bitcoin, Ethereum, and Litecoin. Founded in 2012 and based in San Francisco, California, Coinbase provides various products and services, such as a user-friendly website for transactions, digital wallets, and merchant payment processing tools. The platform allows users to connect their bank accounts to facilitate the buying and selling of cryptocurrencies. Additionally, Coinbase Ventures serves as the company's investment arm, focusing on early-stage startups in the cryptocurrency and blockchain sectors. With a mission to create an open financial system for the world, Coinbase has positioned itself as a significant player in the digital currency market.
Auris Health, Inc. is a company based in Redwood City, California, focused on developing advanced robotics technology for medical applications. Founded in 2007, it specializes in creating innovative solutions for diagnostic and therapeutic bronchoscopic procedures. The company's flagship product, the Monarch Platform, utilizes small cameras and instruments to facilitate endoscopic procedures through natural body openings. This platform incorporates cutting-edge advancements in imaging technology, robotics, endoscope design, sensing, and data science, aiming to enhance patient outcomes and reduce medical costs. Additionally, Auris Health is developing a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its capabilities in the medical robotics field. As a subsidiary of Johnson & Johnson, Auris Health continues to transform medical intervention through its integration of various technological innovations.
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.
BloomAPI Inc. is a Seattle-based company founded in 2015 that specializes in developing software for processing medical records. The firm offers free software installations for medical practices, enabling them to securely and electronically release patient records. BloomAPI aims to democratize access to healthcare data by promoting interoperability among electronic medical records (EMRs). The company focuses on facilitating connections between patients, healthcare providers, and payers, striving to eliminate data monopolies that limit the sharing of information for competitive purposes. Through its initiatives, BloomAPI seeks to simplify healthcare technology and enhance the overall accessibility of medical data.
Kobalt is an independent music services company that provides technology-driven solutions designed to enhance transparency and efficiency for rights owners in the music industry. The company operates through its Music Publishing, Label Services, and Neighbouring Rights divisions, offering a modern alternative to traditional business models. Kobalt empowers artists, songwriters, and publishers by providing real-time reporting through its Kobalt Portal, along with global licensing management, royalty collection, and digital marketing services. With a workforce of over 275 employees and a client roster that includes prominent artists and songwriters, Kobalt represents more than 8,000 creators and 600,000 songs, significantly impacting the music charts. The company aims to ensure fair and accurate payment for its clients while navigating the complexities of the digital music landscape.